(NASDAQ: LXEO) Lexeo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.
Lexeo Therapeutics's earnings in 2025 is -$104,966,000.On average, 12 Wall Street analysts forecast LXEO's earnings for 2025 to be -$147,967,208, with the lowest LXEO earnings forecast at -$161,652,332, and the highest LXEO earnings forecast at -$138,712,415. On average, 11 Wall Street analysts forecast LXEO's earnings for 2026 to be -$117,210,348, with the lowest LXEO earnings forecast at -$168,805,090, and the highest LXEO earnings forecast at -$85,066,730.
In 2027, LXEO is forecast to generate -$126,187,790 in earnings, with the lowest earnings forecast at -$208,145,259 and the highest earnings forecast at -$83,533,996.